ECB opposes BNP Paribas' Axa IM deal capital treatment, Bloomberg News reports-March 2024-www.financetom.com

ECB opposes BNP Paribas' Axa IM deal capital treatment, Bloomberg News reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

ECB opposes BNP Paribas' Axa IM deal capital treatment, Bloomberg News reports

Apr 11, 2025 6:38 AM

April 11 (Reuters) - The European Central Bank has taken

a negative view on applying a rule that might have reduced the

impact on BNP Paribas' capital from its acquisition of

AXA SA's investment management business, Bloomberg

News reported on Friday, citing people familiar with the matter.

(Reporting by Chandni Shah in Bengaluru)

Previous page： Marvell Technology forecasts first quarter revenue below estimates Next page： BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Marvell Technology forecasts first quarter revenue below estimates

Mar 7, 2024

March 7 (Reuters) - Chipmaker Marvell Technology forecast first-quarter revenue below market expectations on Thursday, hurt by weak demand for its custom chips used in artificial intelligence applications. The company expects net revenue to be $1.15 billion, plus or minus 5%, compared with estimates of $1.37 billion, according to LSEG data. ...

BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer

Mar 7, 2024

04:12 PM EST, 03/07/2024 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Thursday it named Cristin Hubbard as chief commercial officer, starting May 20. BioMarin said Hubbard, who most recently served as head of global product strategy at Roche Pharma, will succeed Jeff Ajer. ...

Doman Building Materials Reports 2023 Financial Results

Mar 7, 2024

04:14 PM EST, 03/07/2024 (MT Newswires) -- Doman Building Materials Group Ltd. ( CWXZF ) announced Thursday its fourth quarter and full year 2023 financial results for the period ending Dec. 31, 2023. For the year, consolidated revenues were $2.5 billion, compared to $3.0 billion in 2022, with the decrease largely due to the impact of lower construction materials pricing,...

Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain

Mar 7, 2024

04:12 PM EST, 03/07/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) was up 2.9% in after hours Nasdaq trading after the company on Thursday said its fourth-quarter loss narrowed on a non-cash gain. The development-stage biopharmaceutical company said it lost C$3.9 million, or C$0.05, in the period, compared with a loss of C$8.6 million, or C$0.14, in the year-prior...